34ACTIVITIES
1ORGS REPRESENTED
59BILLS
Revolving door — covered positions
Federal positions Jake held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.
Cong. Affairs Specialist - FDA
Leg. Asst., Leg. Aide/Press Asst., Staff Asst., District Field Rep./Staff Asst. - Cong. Frank Pallone, Jr.
Intern - Sen. Cory Booker
Organizations represented
1Orgs whose LD-2 filings list Jake as an active lobbyist, sorted by activity volume.
Bills they file on
59S. 229615 mentions
S. 65214 mentions
S. 83214 mentions
S. 89114 mentions
S. 93214 mentions
H.R. 94614 mentions
H.R. 126214 mentions
H.R. 149214 mentions
H.R. 221414 mentions
S. 35513 mentions
S. 141413 mentions
S. 195413 mentions
S. 86412 mentions
S. 265812 mentions
H.R. 431712 mentions
+ 44 more bills referenced in their activities
Topics in Filings
88Policy topics Jake files on across all their LD-2 activities.
Inflation Reduction Act×28
Drug cost and pricing policy×28
One Big Beautiful Bill Act×28
Supply chain policy×17
Modernizing and Ensuring PBM Accountability×14
Accountability, and Integrity Now and for the Future×14
Vaccine policy×14
Pharmacy Benefit Manager reform×14
Drug importation policy×14
FDA policy×14
Orphan Drug Act×14
Compounding policy×14
Show all 88 topics (+76 more) ▾
Clinical trial policy×14
Issues 340B drug discount program policy×14
Biosimilar approval and reimbursement policy×14
Artificial intelligence policy×14
Part D redesign and policy×14
Part B policy×14
Medicare rebate policy×14
Center for Medicare and Medicaid Innovation×14
Medicaid rebate policy×14
FDA Modernization×14
BIOSECURE Act×14
Most Favored Nation×14
Biosimilar Red Tape Elimination Act×13
Bipartisan Health Care Act×12
IRA price negotiation expansion policy×12
MAHA Commission Report×12
Make Our Children Healthy Again Competition policy×12
Issues 340B rebate pilot program Patient assistance program policy×12
Biosimilars Access and Affordability Act×12
PBM Price Transparency and Accountability Act×11
Mikaela Naylon Give Kids a Chance Act×11
PBM Reform×11
HELP Copays Act×11
Antimicrobial resistance policy×11
GENErating cost Reductions for U.S×11
Medicare Against Rising Drugs Costs×11
CLEAR LABELS Act×10
Most Favored Patients Act×10
FAIR ACT×10
SECURE Rx Act×10
User fee issues×4
Rural Development×4
Give Kids a Chance Act×3
Antimicrobial resistance×3
Biopharmaceutical innovation policy×3
International intellectual property and market access policy×3
Pricing and reimbursement policy×3
WTO TRIPS waiver policy×3
China outbound investment policy×3
Accelerated approval policy×2
Competition policy×2
Patient assistance program policy×2
Drug shortages policy×2
Insulin policy×2
Medicaid waiver policy×2
Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H×2
Res. 566: Providing for consideration of the Senate amendment to the bill×2
Science, and Related Agencies Appropriations Act, 2026×2
RESTORE Patent Rights Act×2
Protecting Patients from Deceptive Drug Ads Act×1
Innovation in Pediatric Drugs Act×1
Pandemic preparedness policy×1
Saving Seniors Money on Prescriptions Act×1
Military Construction×1
Skinny Labels×1
Big Savings Act×1
Affordable Prescriptions for Patients Act×1
Stop STALLING Act×1
Preserve Access to Affordable Generics and Biosimilars Act×1
Interagency Patent Coordination and Improvement Act×1
Bayh-Dole march-in rights policy×1
Patent thicket policy×1
Patent use codes policy×1
AI patent policy×1
Patent eligibility policy×1
Post-grant proceeding policy×1
Patent submission policy×1
Expedited Acccess to Biosimilars Act×1
MAPS Act×1
Medication Affordability and Patent Integrity Act×1
Orphan Cures Act×1
Prescription Information Modernization×1
MVP Act×1
Legislative Branch×1
Open Payments Expansion Act×1
US-UK Framework Agreement×1
Issue mix
LDA general-issue codes weighted by activity count.
Health Issues14
Medicare/Medicaid14
Trade (domestic/foreign)3
Budget/Appropriations2
Copyright/Patent/Trademark1